The influence of metabolic syndrome and its risk components on serum prostate-specific antigen level

doi:10.3969/j.issn.1673-8640.2014.09.016

Abstract

Abstract: Objective To investigate the influence of metabolic syndrome and its risk components on serum prostate-specific antigen(PSA) level. Methods A total of 5 717 male healthy subjects over 40 years old without the history of prostate cancer, who met the requirements and had integrated data, were enrolled from 3 hospitals.Physical examination and laboratory tests [triglyceride (TG), high-density lipoprotein cholesterol(HDL-C), fasting blood glucose(FBG)and PSA]were performed. According to Chinese Diabetes Society criteria for metabolic syndrome and its risk components, the influence of metabolic syndrome and its risk components on serum PSA level was analyzed statistically. Results The mean age of 5 717 healthy subjects was (53.49±10.64)years old, the prevalence of metabolic syndrome was 27.1%, and the PSA was (1.04±0.72) ng/mL. The PSA levels between metabolic syndrome group and healthy control group were not significantly statistical (P>0.05). After adjusting for age, the partial correlation among body mass index (BMI), FBG and PSA levels was negative, and the correlation coefficients(r) were -0.05 and -0.03, respectively(P<0.05). There was no correlation between metabolic syndrome and its risk components with serum PSA (P>0.05).For analysis of covariance, the age-adjusted means of serum PSA levels by BMI and FBG were cmputed, and they decreased with the increase of BMI and FBG. Conclusions The correlation of serum PSA level with BMI and FBG is negative. The influence of BMI and FBG on PSA level should be considered.

Key words: Prostate-specific antigen, Metabolic syndrome, Prostate tumor

CLC Number:

R446.1

ZHANG Benhong, ZHANG Fei, CHEN Baode, XU Songxiao, CHENG Haien. The influence of metabolic syndrome and its risk components on serum prostate-specific antigen level[J]. , 2014, 29(9): 940-944.

References

[1] Martin RM, Vatten L, Gunnell D, et al. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway[J]. Cancer Causes Control,2009,20(7):1181-1192.
[2] 中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35(5):390-419.
[3] 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议[J]. 中国糖尿病杂志,2004,12(3):156-161.
[4] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies[J]. Lancet, 2004, 363(9403):157-163.
[5] Collier A, Ghosh S, McGlynn B, et al. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review[J]. Am JClin Oncol, 2012, 35(5): 504-509.
[6] Nobes JP, Langley SE, Laing RW. Metabolic syndrome and prostate cancer: a review[J]. Clin Oncol (R Coll Radiol),2009,21(3):183-191.
[7] Beebe-Dimmer JL, Dunn RL, Sarma AV, et al. Features of the metabolic syndrome and prostate cancer in African-American men[J]. Cancer,2007,109(5):875-881.
[8] Laukkanen JA, Laaksonen DE, Niskanen L, et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study[J]. Cancer Epidemiol Biomarkers Prev,2004,13(10):1646-1650.
[9] Lund Haheim L, Wislff TF, Holme I, et al. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years[J]. Am J Epidemiol,2006,164(8):769-774.
[10] 卢一平. 前列腺特异性抗原在前列腺癌中的应用[J]. 中华检验医学杂志,2011,34(6):572-576.
[11] Han JH, Choi NY, Bang SH, et al. Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men[J]. Urology,2008,72(4):749-754.
[12] Kim YJ, Cho YJ, Oh JE, et al. The association between metabolic syndrome and prostate-specific antigen levels[J]. Int J Urol,2008,15(10):905-909.
[13] Jeong IG, Hwang SS, Kim HK, et al. The association of metabolic syndrome and its components with serum prostate-specific antigen levels in a Korean-screened population[J]. Cancer Epidemiol Biomarkers Prev,2010,19(2):371-380.
[14] Moyad MA. Is obesity a risk factor for prostate cancer, and does it even matter A hypothesis and different perspective[J]. Urology,2002,59(4 Suppl 1):41-50.